Dr. Christoph Krisp obtained his PhD in Chemistry and Biomolecular Sciences in 2013 from the Ruhr University Bochum, Bochum, Germany, and the Macquarie University in Sydney, Australia investigating wound healing processes in normal healing wounds and chronic, non-healing wounds from diabetics. ​

He then started a Post-Doc position at the Australian Proteome Analysis Facility (APAF) at the Macquarie University in Sydney, Australia, analyzing melanoma tissue specimen and correlating proteome phenotypes with MEK inhibitor resistant and sensitive phenotypes In patient derived melanoma cell lines. ​

In 2017, Christoph Krisp moved to Hamburg, Germany, to start a second Post-Doc in a Mass Spectrometry Proteomics Core Facility at the University Medical Center Hamburg Eppendorf to focus on proteomic analysis of clinical and biological specimens.​

In summer 2021, Christoph Krisp joint Bruker Daltonics as an Application Development Specialist for Proteomics with focusing on Single Cell Proteomics workflow development.​